Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion - PubMed (original) (raw)

Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion

Jonathan W B Marshall et al. Stroke. 2003 Sep.

Abstract

Background and purpose: NXY-059 has substantial protective effects when administered immediately after the onset of ischemia in a primate model of stroke. This study examined the efficacy of this drug when administered 4 hours after onset, a more clinically relevant time point.

Methods: Before surgery, marmosets were trained and tested on a number of neurological tests, which assessed general neurological function, motor ability, and spatial awareness. Four hours after permanent middle cerebral artery occlusion (pMCAO), marmosets received a bolus of saline (n=13) or NXY-059 (n=13), and osmotic minipumps were implanted, providing 48-hour saline or drug (85 micromol/kg per hour) infusion. The monkeys were retested 3 and 10 weeks after surgery. Finally, infarct size was evaluated with histological analysis.

Results: The unbound plasma NXY-059 concentration was 200+/-9 micromol/L after 24-hour infusion, a concentration well tolerated in stroke patients. Drug treatment ameliorated the long-term motor impairment produced by pMCAO; the marmosets were better at using their contralesional, stroke-affected arm than controls at both 3 and 10 weeks. Saline-treated animals had a debilitating spatial neglect at 3 weeks with residual signs evident at 10 weeks. NXY-059 treatment substantially attenuated neglect at 3 weeks, with no deficit being seen at 10 weeks. NXY-059 reduced the overall infarct size by 28% (saline, 324+/-46 mm3; NXY-059, 234+/-30 mm3) with protection to the cortex, white matter, and subcortical structures.

Conclusions: NXY-059 is an effective neuroprotective agent when administered 4 hours after pMCAO in a primate species, attenuating both motor and spatial neglect. The compound also substantially lessened the volume of cerebral damage.

PubMed Disclaimer

Cited by

Quest for Quality in Translational Stroke Research-A New Dawn for Neuroprotection?
Haupt M, Gerner ST, Bähr M, Doeppner TR. Haupt M, et al. Int J Mol Sci. 2022 May 11;23(10):5381. doi: 10.3390/ijms23105381. Int J Mol Sci. 2022. PMID: 35628192 Free PMC article. Review.
Refocusing Neuroprotection in Cerebral Reperfusion Era: New Challenges and Strategies.
Xiong XY, Liu L, Yang QW. Xiong XY, et al. Front Neurol. 2018 Apr 23;9:249. doi: 10.3389/fneur.2018.00249. eCollection 2018. Front Neurol. 2018. PMID: 29740385 Free PMC article. Review.
Potential circadian effects on translational failure for neuroprotection.
Esposito E, Li W, T Mandeville E, Park JH, Şencan I, Guo S, Shi J, Lan J, Lee J, Hayakawa K, Sakadžić S, Ji X, Lo EH. Esposito E, et al. Nature. 2020 Jun;582(7812):395-398. doi: 10.1038/s41586-020-2348-z. Epub 2020 Jun 3. Nature. 2020. PMID: 32494010 Free PMC article.
Long-term neuroprotection from a potent redox-modulating metalloporphyrin in the rat.
Sheng H, Yang W, Fukuda S, Tse HM, Paschen W, Johnson K, Batinic-Haberle I, Crapo JD, Pearlstein RD, Piganelli J, Warner DS. Sheng H, et al. Free Radic Biol Med. 2009 Oct 1;47(7):917-23. doi: 10.1016/j.freeradbiomed.2009.05.039. Epub 2009 Jul 22. Free Radic Biol Med. 2009. PMID: 19631268 Free PMC article.
Neuroprotection for stroke: current status and future perspectives.
Minnerup J, Sutherland BA, Buchan AM, Kleinschnitz C. Minnerup J, et al. Int J Mol Sci. 2012;13(9):11753-11772. doi: 10.3390/ijms130911753. Epub 2012 Sep 18. Int J Mol Sci. 2012. PMID: 23109881 Free PMC article. Review.

Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion - PubMed (original) (raw)